nach oben

Social Psychiatry and Psychiatric Epidemiology

Erschienen in:

01.07.2015 | Original Paper

Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands

verfasst von: Els F. van den Ban, Patrick C. Souverein, Herman van Engeland, Hanna Swaab, Toine C. G. Egberts, Eibert R. Heerdink

Erschienen in: Social Psychiatry and Psychiatric Epidemiology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Differences in incidence and prevalence of ADHD medication use between ethnic groups have been reported. Goal of this study was to determine whether there are also differences in usage patterns of ADHD medication among native Dutch children and adolescents and those with a Moroccan, Turkish and Surinam cultural background in the Netherlands between 1999 and 2010.

Methods

In a cohort of ADHD patients <19 years (N = 817) incident use and discontinuation of ADHD medication were measured for ethnicity and adjusted for age, gender and socio-economic status.

Results

A significant higher proportion of ADHD-diagnosed patients from Moroccan (32 %) and Turkish (42 %) cultural background never used ADHD medication compared to Dutch natives (21 %). One-fifth of native Dutch and Turkish patients already used ADHD medication before the ADHD diagnosis date. Discontinuation of ADHD medication within 5 years was significantly higher in Moroccan [HR 2.4 (95 % CI 1.8–3.1)] and Turkish [HR 1.7 (95 % CI 1.1–2.6)] patients. A sensitivity analysis with a zip code-matched comparison between Dutch natives and non-natives showed similar results, suggesting this effect is probably not explained by socio-economic status (SES).

Conclusion

Differences are found in prescribing and use of ADHD medication between patients with a different cultural background. Native Dutch and Turkish patients start more frequently with ADHD medication before the ADHD diagnose date, which can be an indication of differences in either referral patterns and/or access to care. A higher percentage of patients with a Moroccan and Turkish cultural background never start using ADHD medication at all and discontinuation rate is higher compared to Dutch natives and Surinamese.

Aacap ADHD Guideline (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894–921CrossRef

Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K et al (2007) British Association for Psychopharmacology. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21(1):10–41PubMedCrossRef

Atkinson M, Hollis C (2010) NICE guideline: attention deficit hyperactivity disorder. Arch Dis Child Educ Pract Ed 95(1):24–27PubMedCrossRef

Murphy K, Barkley R (1996) Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disorder 3:147–161CrossRef

McDonnell MA, Glod C (2003) Prevalence of psychopathology in preschool-age children. Child Adolesc Psychiatr Nurs 16(4):141–152CrossRef

Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O et al (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163(4):716–723PubMedCentralPubMedCrossRef

Ten Have M, Graaf de R, Dorsselaer S, Verdurmen J, Land van’t H, Vollenbergh W et al (2006) Prevalentie van impulsstoornissen. Resultaten van the European Study of Epidemiology of Mental Disorders (ESEMeD). Trimbos Instituut, Utrecht

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. Am J Psychiatry 164(6):942–948PubMedCrossRef

de Ridder T, Bruffaerts R, Danckaerts M, Bonnewyn A, Demyttenaere K (2008) ADHD in de Belgische bevolking; een epidemiologische exploratieve studie. Tijdschr Psychiatr 50(8):499–508PubMed

10.

Michielsen M, Semeijn E, Comijs HC, van de Ven P, Beekman AT, Deeg DJ et al (2012) Prevalence of attention-deficit hyperactivity disorder in older adults in the Netherlands. Br J Psychiatry 201(4):298–305PubMedCrossRef

11.

Wichstrøm L, Berg-Nielsen TS, Angold A, Egger HL, Solheim E, Sveen TH (2012) Prevalence of psychiatric disorders in preschoolers. J Child Psychol Psychiatry 53(6):695–705PubMedCrossRef

12.

Robison L, Sclar D, Traer T, Galins R (1999) National trends in prevalence of attention-deficit/hyperactivity disorder and the prescription of methylphenidate among school-age children: 1990–1995. Clin Pediatrics 38:209–217CrossRef

13.

Miller A, Lalonde C, McGrail K, Armstrong R (2001) Prescription of methylphenidate to children and youth, 1990–1996. Can Med Assoc J 165:1489–1494

14.

Schirm E, Tobi H, Zito J, de Jong-van den Berg LT (2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics 108:E25–E29PubMedCrossRef

15.

Zito J, Safer D, dosReis S et al (2000) Trends in prescribing of psychotropic medications to preschoolers. JAMA 83:1025–1030CrossRef

16.

Reid R, Hakendorf P, Prosser B (2002) Use of stimulant medication for ADHD in South Australia. J Am Acad Child Adolesc Psychiatry 41:906–913PubMedCrossRef

17.

Hugtenburg J, Heerdink E, Egberts A (2004) Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol 60:377–379PubMedCrossRef

18.

Faber A, de Jong-van den Berg LT, van den Berg PB, Tobi H (2005) Psychotropic comedication among stimulant-treated children in the Netherlands. J Child Adolesc Psychofarm 15:38–43CrossRef

19.

Robison L, Sclar D, Skaer T (2005) Trends in ADHD and stimulant use among adults: 1995–2002. Psychiatr Serv 56:1497PubMedCrossRef

20.

Vinker S, Vinker R, Elhayany A (2006) Prevalance of methylphenidate use among Israeli children: 1998–2004. Clin Drug Investig 26:161–167PubMedCrossRef

21.

Castle L, Aubert R, Verbrugge R, Khalid M, Epstein R (2007) Trends in medication treatment for ADHD. J Att Disord 10:335–342CrossRef

22.

Zito J, Safer D, Satish Valluri M, Gardner J, Korelitz J, Mattison D (2007) Psychotherapeutic medication prevalence in medicaid-insured preschoolers. J Child Adolesc Psychofarm 17:195–203CrossRef

23.

Winterstein A, Gerhard T, Shuster J, Zito J, Johnson M (2008) Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. Ann Pharmacother 42:24–31PubMedCrossRef

24.

van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T (2010) Incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001–2006. J Child Adolesc Psychopharmacol 20:55–61PubMedCrossRef

25.

Comer J, Olfson M, Mojtabai R (2010) National trends in child and adolescent psychotropic polypharmacy in office based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 49(10):1001–1010PubMedCentralPubMedCrossRef

26.

Hodgkins P, Sasane R, Meijer WM (2011) Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 3:188–203CrossRef

27.

Fullerton CA, Epstein AM, Frank RG, Normand SL, Fu CX, McGuire TG (2012) Medication use and spending trends among children with ADHD in Florida’s Medicaid program, 1996–2005. Psychiatr Serv 63(2):115–121PubMedCrossRef

28.

Lindemann C, Langner I, Kraut A, Banaschewski T, Schad-Hansjosten T, Petermann U et al (2012) Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. J Child Adolesc Psychopharmacol 22(4):307–314PubMedCrossRef

29.

Zuvekas S, Vitiello B (2012) Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 169(2):160–166PubMedCentralPubMedCrossRef

30.

Raghavan R, Brown DS, Thompson H, Ettner SL, Clements LM, Key W (2012) Medicaid expenditures on psychotropic medications for children in the child welfare system. J Child Adolesc Psychopharmacol 22(3):182–189PubMedCentralPubMedCrossRef

31.

Zito JM, Safer DJ, dosReis S, Magder LS, Riddle MA (1997) Methylphenidate patterns among medicaid youths. Psychopharmacol Bull 33(1):143–147PubMed

32.

Blanco C, Patel SR, Liu L, Jiang H, Lewis-Fernández R, Schmidt AB et al (2007) National trends in ethnic disparities in mental health care. Med Care 45(11):1012–1019PubMedCrossRef

33.

Bauermeister JJ, Canino G, Bravo M, Ramírez R, Jensen PS, Chavez L et al (2003) Stimulant and psychosocial treatment of ADHD in Latino/Hispanic children. J Am Acad Child Adolesc Psychiatry 42(7):851–855PubMedCrossRef

34.

Bussing R, Zima BT, Mason D, Hou W, Garvan CW, Forness S (2005) Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15(1):78–87PubMedCrossRef

35.

dosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL (2005) Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 15(1):68–77PubMedCrossRef

36.

Radigan M, Lannon P, Roohan P, Gesten F (2005) Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population. J Child Adolesc Psychopharmacol 15(1):44–56PubMedCrossRef

37.

Raghavan R, Zima BT, Andersen RM, Leibowitz AA, Schuster MA, Landsverk J (2005) Psychotropic medication use in a national probability sample of children in the child welfare system. J Child Adolesc Psychopharmacol 15(1):97–106PubMedCrossRef

38.

Stevens J, Harman JS, Kelleher KJ (2005) Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol 15(1):88–96PubMedCrossRef

39.

Zito JM, Safer DJ, Zuckerman IH, Gardner JF, Soeken K (2005) Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatr Serv 56(2):157–163PubMedCrossRef

40.

Bruckner TA, Hodgson A, Mahoney CB, Fulton BD, Levine P, Scheffler RM (2012) Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications. Pharmacoepidemiol Drug Saf 21(4):442–449PubMedCrossRef

41.

Brown RT, Sexson SB (1988) A controlled trial of methylphenidate in black adolescents. Attentional, behavioral, and physiological effects. Clin Pediatr (Phila) 27(2):74–81CrossRef

42.

Arnold LE, Elliot M, Sachs L, Bird H, Kraemer HC, Wells KC et al (2003) Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol 71(4):713–727PubMedCrossRef

43.

Bauermeister JJ, Bird HR, Shrout PE, Chavez L, Ramírez R, Canino G (2011) Short-term persistence of DSM-IV ADHD diagnoses: influence of context, age, and gender. Am Acad Child Adolesc Psychiatry 50(6):554–562CrossRef

44.

Statistics Netherlands (CBS) (2005) StatLine database. http://www.cbs.nl/NR/rdonlyres/92AA630F-7BD8-4DFB-B27D-A7229D329204/0/2005eindrapportmgzpub.pdf. Accessed 16 Oct 2014

45.

Statistics Netherlands (CBS) (2005) StatLine database. http://www.cbs.nl/nl-NL/. Accessed 3 Jan 2014

46.

Zwirs BW, Burger H, Schulpen TW, Wiznitzer M, Fedder H, Buitelaar JK (2007) Prevalence of psychiatric disorders among children of different ethnic origin. J Abnorm Child Psychol 35(4):556–566PubMedCrossRef

47.

Boon E, De Haan AM, De Boer S (2010) Verschillen in etnische achtergrond van forensische en reguliere jeugd-ggz-cliënten. Kind en Adolescent 13:16–28CrossRef

48.

Zwirs BW, Burger H, Buitelaar JK, Schulpen TW (2006) Ethnic differences in parental detection of externalizing disorders. Eur Child Adolesc Psychiatry 15(7):418–426PubMedCrossRef

49.

Nuijen J, Romijn G, van Mierlo F, van der Zanden A, Onrust S (2010) Psychische problematiek bij kinderen en jongeren: 135 Over ontwikkelingen in het vóórkomen, de toegang tot en het gebruik van de jeugd-GGZ Trimbos-instituut, Utrecht, Netherlands, Institute of Mental health and addiction, pp 135–175

50.

Scheppers E, van Dongen E, Dekker J, Geertzen J, Dekker J (2006) Potential barriers to the use of health services among ethnic minorities: a review. Fam Pract 23(3):325–348PubMedCrossRef

51.

Alegria M, Lin J, Green J, Sampson N, Gruber M, Kessler M (2012) Role of referrals in mental health service disparities for racial and ethnic minority youth. J Am Ac Child Adolesc Psychiatry 51(7):703–711.e2CrossRef

52.

Verhulp EE, Stevens GW, van de Schoot R, Vollebergh WA (2013) Understanding ethnic differences in mental health service use for adolescents’ internalizing problems: the role of emotional problem identification. Eur Child Adolesc Psychiatry 22(7):413–421PubMedCrossRef

53.

Wittkampf L, Smeets H, Knol M, Geerlings M, Bram A, de Wit N (2010) Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Soc Psychiat Epidemiol 45:819–826CrossRef

54.

Lipkin PH, Cozen MA, Thompson RE, Mostofsky SH (2005) Stimulant dosage and age, race, and insurance type in a sample of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15(2):240–248PubMedCrossRef

55.

Knol F (2012) Development status of Dutch neighborhoods 1998–2010. Sociaal Cultureel Planbureau (in Dutch)

56.

Tolan PH, Henry D (1996) Patterns of psychopathology among urban poor children: comorbidity and aggression effects. J Consult Clin Psychol 64(5):1094–1099PubMedCrossRef

57.

Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H et al (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 54(5):527–535PubMedCrossRef

58.

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J et al (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476–495PubMedCrossRef

59.

Brown R, Pacini J (1989) Perceived family functioning, marital status, and depression in parents of boys with attention deficit disorder. J Learn Disab 22(9):581–587CrossRef

60.

Barkley R, Guevremont D, Anastopoulos A, DuPaul G, Shelton T (1993) Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 92(2):212–218PubMed

61.

Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O’Brien PC (2001) Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. J Am Med Assoc 285(1):60–66CrossRef

62.

Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A (2003) Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Ac Child Adolesc Psychiatry 42(12):1415–1423CrossRef

63.

Swensen A, Birnbaum H, Hamadi R, Greenberg P, Cremieux P, Secnik K (2004) Incidence and costs of accidents among attention/deficit disorder patients. J Adolesc Health 35:346e1–346e9CrossRef

64.

Hakkaart-van Roijen L, Zwirs B, Bouwmans C, Tan S, Schulpen T, Vlasveld L et al (2007) Social costs and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 16:316–326PubMedCrossRef

65.

Coghill D, Soutello C, d’ Aubuisson C, Preuss U, Lindback T, Silverberg M et al (2008) Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. J Child Adolesc Psychiatry Ment Health 2(1):31CrossRef

66.

Sobanski E, Brüggemann D, Alm B, Kern S, Philipsen A, Schmalzried H et al (2008) Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 23:142–149PubMedCrossRef

67.

Bussing R, Mason D, Bell L, Porter P, Garvan C (2010) adolescent outcome of childhood attention-deficit/hyperactivity disorder in a diverse community sample. J Am Acad Cild Adolesc Psychiatry 49(6):595–605

68.

Meyers J, Classi P, Wietecha L, Candrill S (2010) Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States. Child Adolesc Psychiatry Ment Health 14(4):31CrossRef

69.

Charach A, Yeung E, Climans T, Lillie E (2011) Childhood attention deficit/hyperactivity disorder and the future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 50:9–21PubMedCrossRef

70.

Lee S, Humphreys K, Flory K, Liu R, Glass K (2011) Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev 31:328–341PubMedCentralPubMedCrossRef

71.

Ginsberg Y, Långström N, Larsson H, Lichtenstein P (2013) ADHD and criminality: could treatment benefit prisoners with ADHD who are at higher risk of reoffending? Expert Rev Neurother 13(4):345–348PubMedCrossRef

72.

Lichtenstein P, Halldner L, Zetterqvist J, Sjölander A, Serlachius E, Fazel S et al (2012) Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367(21):2006–2014PubMedCentralPubMedCrossRef

73.

Statistics Netherlands (CBS) (2010) StatLine database. http://www.cbs.nl/nl-NL/menu/themas/gezondheid-welzijn/publicaties/artikelen/archief/2010/2010-3087-wm.htm. Accessed 16 Oct 2014

74.

Statistics Netherlands (CBS) (2007) StatLine database. Bevolkingstrends, 4e kwartaal. http://www.cbs.nl. Accessed 16 Oct 2014

Titel: Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands
verfasst von: Els F. van den Ban
Patrick C. Souverein
Herman van Engeland
Hanna Swaab
Toine C. G. Egberts
Eibert R. Heerdink
Publikationsdatum: 01.07.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Social Psychiatry and Psychiatric Epidemiology / Ausgabe 7/2015
Print ISSN: 0933-7954
Elektronische ISSN: 1433-9285
DOI: https://doi.org/10.1007/s00127-015-1068-4

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands